Transcatheter tricuspid-valve replacement significantly improved symptoms and quality of life compared to medical therapy in patients with severe tricuspid regurgitation.
Does transcatheter tricuspid-valve replacement improve outcomes in patients with severe tricuspid regurgitation compared to medical therapy alone?
Transcatheter tricuspid-valve replacement is superior to medical therapy alone for improving symptoms and quality of life in patients with severe tricuspid regurgitation.
Tasa de eventos absoluta: 0% vs 0%
For patients with severe tricuspid regurgitation, transcatheter tricuspid-valve replacement was superior to medical therapy alone for the primary composite outcome, driven primarily by improvements in symptoms and quality of life. (Funded by Edwards Lifesciences; TRISCEND II ClinicalTrials.gov number, NCT04482062.).
“While neither trial demonstrated a mortality benefit, these two trials showed that both T-TEER and TTVR were associated with a reduction in TR, reduction of symptoms and improvement in quality of life compared to medical therapy alone.”
Rapidly evolving field of tricuspid interventions with multiple devices in trials.
Hahn et al. (Wed,) reported a other. Transcatheter tricuspid-valve replacement significantly improved symptoms and quality of life compared to medical therapy in patients with severe tricuspid regurgitation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: